Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2013:2013:195637.
doi: 10.1155/2013/195637. Epub 2013 Mar 7.

Pregnancy outcomes in HIV-infected women receiving long-term isoniazid prophylaxis for tuberculosis and antiretroviral therapy

Allan W Taylor  1 , Barudi Mosimaneotsile, Unami Mathebula, Anikie Mathoma, Ritah Moathlodi, Irene Theebetsile, Taraz Samandari
Affiliations
Randomized Controlled Trial

Pregnancy outcomes in HIV-infected women receiving long-term isoniazid prophylaxis for tuberculosis and antiretroviral therapy

Allan W Taylor et al. Infect Dis Obstet Gynecol. 2013.

Abstract

Objective: While 6- to 12-month courses of isoniazid for tuberculosis prevention are considered safe in pregnant women, the effects of longer-term isoniazid prophylaxis or isoniazid in combination with antiretroviral therapy (ART) are not established in human-immunodeficiency-virus-(HIV-) infected women who experience pregnancy during the course of therapy.

Design: Nested study of pregnancy outcomes among HIV-infected women participating in a placebo-controlled, TB-prevention trial using 36 months daily isoniazid. Pregnancy outcomes were collected by interview and record review.

Results: Among 196 pregnant women, 103 (52.6%) were exposed to isoniazid during pregnancy; all were exposed to antiretroviral drugs. Prior to pregnancy they had received a median of 341 days (range 1-1095) of isoniazid. We observed no isoniazid-associated hepatitis or other severe isoniazid-associated adverse events in the 103 women. Pregnancy outcomes were 132 term live births, 42 premature births, 11 stillbirths, 8 low birth weight, 6 spontaneous abortions, 4 neonatal deaths, and 1 congenital abnormality. In a multivariable model, neither isoniazid nor ART exposure during pregnancy was significantly associated with adverse pregnancy outcome (adjusted odds ratios 0.6, 95% CI: 0.3-1.1 and 1.8, 95% CI 0.9-3.6, resp.).

Conclusions: Long-term isoniazid prophylaxis was not associated with adverse pregnancy outcomes, such as preterm delivery, even in the context of ART exposure.

PubMed Disclaimer

References

    1. Reid A, Scano F, Getahun H, et al. Towards universal access to HIV prevention, treatment, care, and support: the role of tuberculosis/HIV collaboration. The Lancet Infectious Diseases. 2006;6(8):483–495. - PubMed
    1. Samandari T, Agizew TB, Nyirenda S, et al. 6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial. The Lancet. 2011;377(9777):1588–1598. - PubMed
    1. Martinson N, Barnes G, Msandiwa R, Moulton L, Gray G, McIntyre J, et al. Novel regimens for treating latent TB in HIV-infected adults in South Africa: a randomized clinical trial. Proceedings of the 16th Conference on Retroviruses and Opportunistic Infections; 2009; Montreal, Canada.
    1. World Health Organization. Guidelines for Intensified Tuberculosis Case Finding and Isoniazid Preventive Therapy for People Living with HIV in Resource Constrained Settings. Geneva, Switzerland: World Health Organization; 2011.
    1. UNAIDS. AIDS epidemic update, November 2009.

Publication types